Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DAT-1604 Tablets as Monotherapy in the Advanced Solid Tumor
Latest Information Update: 11 Jun 2025
At a glance
- Drugs DAT 1604 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Danatlas Pharmaceuticals
Most Recent Events
- 11 Jun 2025 New trial record